N4 Pharma Plc (FRA:0GO)

N4 Pharma Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	0.01	0.01	0	-	-	-
Revenue	0.01	0.01	0	-	-	-
Revenue Growth (YoY)	20.60%	272.86%	-	-	-	-
Gross Profit	0.01	0.01	0	-	-	-
Selling, General & Admin	0.86	0.84	0.72	0.62	0.66	0.66
Research & Development	0.34	0.39	0.62	0.58	1.18	0.9
Operating Expenses	1.21	1.23	1.34	1.19	1.84	1.56
Operating Income	-1.2	-1.22	-1.34	-1.19	-1.84	-1.56
Interest & Investment Income	0	-	-	0	0	-
Currency Exchange Gain (Loss)	-	-	-	-	-	-0
Other Non Operating Income (Expenses)	-	-	-0.09	-	-	-0
EBT Excluding Unusual Items	-1.2	-1.22	-1.42	-1.19	-1.84	-1.57
Pretax Income	-1.2	-1.22	-1.42	-1.19	-1.84	-1.57
Income Tax Expense	-0.07	-0.1	-0.15	-0.16	-0.3	-0.26
Earnings From Continuing Operations	-1.13	-1.12	-1.28	-1.03	-1.54	-1.3
Minority Interest in Earnings	0.03	0.06	0.01	-	-	-
Net Income	-1.1	-1.06	-1.27	-1.03	-1.54	-1.3
Net Income to Common	-1.1	-1.06	-1.27	-1.03	-1.54	-1.3
Shares Outstanding (Basic)	486	340	243	186	181	136
Shares Outstanding (Diluted)	486	341	243	186	181	136
Shares Change (YoY)	80.86%	40.34%	30.29%	2.95%	32.85%	36.08%
EPS (Basic)	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-17000.69%	-16768.76%	-68377.83%	-	-	-
Profit Margin	-15600.13%	-14537.52%	-64993.91%	-	-	-
EBIT	-1.2	-1.22	-1.34	-1.19	-1.84	-1.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.